Phase III Starts Early Next Year
Intarcia Pumps Up with $210M for Once-Yearly Exenatide Bid
By Randy Osborne
Monday, November 19, 2012
Privately held Intarcia Therapeutics Inc.'s subcutaneous, osmotic-pump method of delivering the glucagon-like peptide-1 receptor agonist exenatide will enter Phase III trials in the first quarter of next year, thanks to a whopping $210 million in new cash, gained through a pair of investments.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.